AzTrials
AzTrials

AchalasiaNCT06042127

POEM-F for Achalasia International Study

A study testing POEM-F and Conventional POEM in people with Achalasia, run by Chinese University of Hong Kong at 7 sites in 4 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Per-oral endoscopic myotomy (POEM) has emerged as the endoscopic treatment of choice for achalasia, offering comparable symptom relief with laparoscopic Heller's cardiomyotomy. The main concern with POEM is the higher incidence of post-procedure gastroesophageal reflux disease (GERD), occurring in up to 50-60% of… Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Achalasia
What is being tested?
POEM-F and Conventional POEM
Could I receive a placebo?
No, everyone receives an active treatment
How many people
81 participants
Where
7 sitesin 4 countries
Study dates
1 Dec 2023to 31 Oct 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adult patient (age ≥18 and ≤65 years-old) and with symptomatic achalasia type I or II.
  • Capability of understanding and complying with the study requirements, including filling the Eckardt Score, GERD-HRQL and RSI questionnaire and signing the informed consent form.
  • Patients with achalasia type I, II or III who are one of the following:
  • Treatment naïve, or
  • Failed prior through-the-scope balloon dilation, Savary or pneumatic dilation

Who cannot join

  • Patients unable or unwilling to provide consent.
  • Previous esophageal or gastric surgery.
  • Prior achalasia treatment including Heller myotomy, POEM.
  • Sigmoid achalasia, or significant esophageal dilatation >6cm in lower esophagus
  • Disrupted mucosal integrity at the distal esophagus, eg. Ulcer, fibrotic scars etc
  • Patients with large hiatal hernias (axial length > 2 cm and Hill grade >2).
Show all 10Show fewer
  • Patients with significant cardiorespiratory comorbidities which may limit their ability to undertake general anesthesia for the procedure, including ASA grade III or above.
  • Patients with obesity (Body Mass Index (BMI) ≥ 30).
  • Pregnant women or those planning pregnancy or breastfeeding women.
  • Uncorrectable coagulopathy defined by international normalized ratio (INR) > 1.5 or platelet count < 50000/µl.

Trial locations and contacts

7 sites in 4 countries. Contact the study team or a site near you to ask about taking part.

Hon Chi Yip, FRCSEd contact

35052627

hcyip@surgery.cuhk.edu.hk

7 sites in 4 countries

India4 sites, 4 recruiting
  • Post Graduate Institute of Medical Education and Research

    Chandigarh

    Jayanta Samanta, dj_samanta@yahoo.co.in

    Jayanta Samanta

    Not yet recruiting
  • Asian Institute of Gastroenterology

    Hyderabad

    Mohan Ramchandani, ramchandanimohan@gmail.com

    Mohan Ramchandani

    Not yet recruiting
  • Baldota Institute of Digestive Sciences

    Mumbai

    Amit Maydeo, amitmaydeo@gmail.com

    Amit Maydeo

    Not yet recruiting
  • Deenanath Mangeshkar Hospital & Research Center

    Pune

    Amol Bapaye, amolbapaye@gmail.com

    Amol Bapaye

    Not yet recruiting

Other trials in India

United States1 site, 1 recruiting
  • Johns Hopkins Hospital

    Baltimore, Maryland, 21287

    Mouen Khashab, mkhasha1@jhmi.edu

    Farimah Fayyaz

    Not yet recruiting

Other trials in United States

China1 site, 1 recruiting
  • Nanfang Hospital, Southern Medical University

    Guangzhou

    Xiaobei Luo, luoxiaobei63@126.com

    Xiaobei Luo

    Not yet recruiting

Other trials in China

Hong Kong1 site, 1 recruiting
  • The Chinese University of Hong Kong

    Hong Kong

    Hon Chi Yip, FRCSEd, +85235052627, hcyip@surgery.cuhk.edu.hk

    Recruiting

Other trials in Hong Kong

About this study

Official title: Per-oral Endoscopic Myotomy With Fundoplication for Achalasia - an International Multicenter Randomized Controlled Trial

Per-oral endoscopic myotomy (POEM) has emerged as the endoscopic treatment of choice for achalasia, offering comparable symptom relief with laparoscopic Heller's cardiomyotomy. The main concern with POEM is the higher incidence of post-procedure gastroesophageal reflux disease (GERD), occurring in up to 50-60% of patients. In order to reduce the risk of GERD, endoscopic fundoplication has been developed as a novel procedure mimicking surgical anterior partial fundoplication that can be performed in the same session as POEM (POEM-F). Case series of POEM-F in patients with achalasia reported encouraging outcomes of low GERD rate of ~12% at 1 year. Prospective comparative data between POEM-F and conventional POEM on post-procedure GERD is current lacking. The investigators therefore designed an international multicenter prospective randomized study to investigate the efficacy of POEM-F. The investigators postulate that POEM-F could reduce the incidence of post-procedure GERD when compared with conventional POEM.

This is an international multicenter randomized controlled trial conducted between high volume expert centers from Hong Kong SAR, China, India and United States of America. Adult patients with manometry confirmed achalasia would be randomised to undergo POEM-F or POEM. The procedure would be performed by experts with vast experience in POEM. The primary outcome is the incidence of post-procedure GERD at 1 year, defined by the updated Lyon consensus. Secondary outcomes include technical and clinical success rates, adverse events, post-POEM endoscopic and manometry findings as well as patients' symptom scores.

Read more

Sample size calculation Based on existing pilot comparative data on POEM-F and POEM, it is estimated that 84 patients would be required to demonstrate a difference in post-procedure GERD of 47.6% to 18.2%, with 80% power and false positive rate of 0.05, accounting for 10% loss to follow-up.

Purpose and potential The current study proposal could demonstrate the superiority of POEM-F over POEM in reducing post-procedural GERD. It would also demonstrate the safety and reproducibility of the technique in expert centers across the globe. It could potentially replace conventional POEM as the preferred minimally invasive endoscopic treatment for achalasia.

Read the detailed description

Achalasia is the most common esophageal motility disorder worldwide, with an annual incidence of 1.6 per 100'000 individual and prevalence of 10 per 100'000 population. The incidence of achalasia has been dramatically rising over the past decade. A study conducted in Chicago suggested that over the 10 years from 2004 to 2014, the incidence and prevalence of achalasia were two- to threefold greater than estimates would have predicted. The likely explanation to the rise in incidence is an increased awareness of this condition and widespread availability of accurate diagnostic test with high resolution manometry. The cardinal features of achalasia include failed relaxation of lower esophageal sphincter and absent esophageal peristalsis. Owing to the benign nature of the disease, patients suffering from it would experience longstanding debilitating symptoms of dysphagia, chest pain, regurgitation, resulting in poor quality of life. In the past, laparoscopic Heller's cardiomyotomy with partial fundoplication and endoscopic pneumatic dilatation were considered as treatment options for achalasia.

In the past 10 years, per-oral endoscopic myotomy (POEM) has emerged as the incisionless minimally invasive endoscopic treatment of choice for achalasia. This Natural Orifice Transluminal Endoscopic Surgical (NOTES) technique involves mucosal incision and creation of a submucosal tunnel in the distal esophagus down to gastric cardia, followed by esophageal and gastric myotomy. Since the procedure was first reported by Inoue H, et al in 2010, it has seen worldwide acceptance as first-line therapy. POEM has been associated with excellent relief of dysphagia and achalasia-related symptoms with a low and acceptable adverse event rate of 0.5%. In a previous randomised controlled trial, POEM had a higher treatment success rate than pneumatic dilatation. When compared with laparoscopic Heller's cardiomyotomy, POEM was associated with at least similar treatment efficacy and a trend towards reduced short term adverse event. POEM could perform even better than surgical myotomy in patients with type III achalasia.

The main limitation of POEM is the incidence of gastroesophageal reflux disease (GERD) post-POEM. Kumbhari et al. looked at rates of GERD after POEM on patients who underwent subsequent objective pH testing. A total of 282 patients were included in this analysis from multiple centers in America, Asia, and Europe. About 58% of patients had objective evidence of abnormal acid exposure, with 23% showing evidence of esophagitis. More concerning, however, was that 60% of the patients with GERD were completely asymptomatic. This highlights an important issue at hand that many patients, either related to the propensity of GERD to be silent or the nature of achalasia to develop and insensate esophagus, do not report symptoms while showing high rates of GERD. POEM has been found to be consistently associated with higher rate of GERD than conventional Heller's cardiomyotomy or pneumatic dilatation across multiple studies.

Supported by evidence demonstrating the efficacy of partial fundoplication during Heller's operation, there has been a significant interest in performing fundoplication after POEM during the same session to prevent the development of post-POEM GERD. Inoue et al. pioneered the technique of POEM-F that mimics the surgical Dor (anterior partial fundoplication) procedure. In the pilot study, technical success was achieved in all 21 patients, and all but one had an intact fundoplication wrap on upper endoscopy at a 1-month follow-up. Four more studies conducted in Japan and India have reported good early outcomes with POEM-F (Technical success of 85-100%) for achalasia. No severe adverse event has been reported in these studies which reiterates the safety of this procedure. In the longest follow-up study on POEM-F, GERD diagnosed by an abnormal esophageal acid exposure was seen in 11.1% of the 21 cases at one-year follow-up: comparable (8.8%) to a large meta-analysis of 4871 Heller's cardiomyotomy with fundoplication procedures.

To date, no prospective multicenter randomised study has been conducted to compare the efficacy of POEM-F with conventional POEM in reducing post-procedure GERD. Therefore, in this study, the investigators aim to evaluate the of POEM-F in patients with achalasia through an international multicenter randomized controlled trial.

Conditions
Achalasia
Being tested
POEM-F, Conventional POEM
Keywords
POEM, Fundoplication, GERD
Medical subject headings
Esophageal Achalasia, Gastroesophageal Reflux

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • POEM-FProcedure or surgery

    POEM-F would be performed as described in the arms section

  • Conventional POEMProcedure or surgery

    Anterior POEM performed as described in the arms section

Study groups in NCT06042127
Study groupRoleWhat they receive
Per-oral endoscopic myotomy with fundoplicationExperimentalThe detail of the procedure has been reported in the literature. After completion of myotomy as per conventional anterior POEM, a serosal incision would be made at the level of the GE junction below the diaphragmatic crus. The peritoneal cavity would then be entered and the anterior gastric wall could be identified. A detachable endoloop would be introduced alongside the endoscope with the guidance of endoscopic clip. Three to four clips would be applied to the anterior gastric fundus while additional 3-4 clips would be applied to the edge of the submucosal tunnel, all anchoring to the endoloop. Upon tightening of the endoloop the anterior fundus would be approximated to the esophagogastric junction and thus completing the partial anterior fundoplication. Abdominal paracentesis to treat capnoperitoneum would be performed as required based on patient's clinical condition.
Receives: Procedure: POEM-F
Conventional POEMActive comparatorConventional per-oral endoscopic myotomy An anterior POEM would be performed per usual manner described in the literature. The procedure would be performed under general anaesthesia by expert endoscopists with at least 50 case experience of conventional POEM and 5 cases experience of POEM-F. The requirement of POEM experience is based on a recent multicenter study of learning curve by Fujiyoshi Y, et al. The procedure would follow the current recommendations from expert panel in reducing GER, including avoidance of excessive gastric myotomy and preservation of the sling fibers are the gastric cardia. The length of the esophageal and gastric myotomy is standardized at 5cm and 2cm respectively
Receives: Procedure: Conventional POEM

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Post-procedure rate of gastroesophageal reflux

    Defined by updated Lyon 2.0 consensus as fulfilling one or more of the criteria:

    1. Endoscopic erosive esophagitis, LA grade B or above
    2. Long segment Barrett's esophagus
    3. Peptic esophageal stricture
    4. 24-hour pH study with acid exposure time >6% Both endoscopy and pH study to be performed with proton pump inhibitor stopped for 4 weeks

    Measured: 1 year

Secondary outcomes (18)
  1. Clinical success rate of procedure

    Post-treatment Eckhardt score <=3

    Measured: 1 year

  2. Adverse event of procedure

    frequency of severe adverse events with probable or definite attribution to the procedure based on the American Society of Gastrointestinal Endoscopy (ASGE) lexicon as well as Clavien Dindo classification

    Measured: 30 day

  3. Technical success rate of procedure

    Completing all steps of the intended procedure successfully in the same session

    Measured: 1 day

  4. Procedure time

    Procedure time of the intended procedure in minutes

    Measured: 1 day

  5. Erosive esophagitis on post-procedure endoscopy

    The presence of erosive esophagitis as well as the grading on post-procedure endoscopy

    Measured: 1 year

  6. Fundoplication wrap integrity on post-procedure endoscopy

    Endoscopic appearance of fundoplication wrap on retroflexion in the stomach.

    1. Intact - wrap is completely visualised
    2. Indistinct - wrap is visualised but appears to be loosened
    3. Absent - the wrap is completely not visible

    Measured: 1 year

  7. Distensibility index on EndoFLIP, premyotomy

    Distensibility index (mm2/mmHg) using EndoFLIP

    Measured: During index procedure, before myotomy

  8. Distensibility index on EndoFLIP, post myotomy

    Distensibility index (mm2/mmHg) using EndoFLIP

    Measured: During index procedure, after myotomy

  9. Distensibility index on EndoFLIP, post fundoplication

    Distensibility index (mm2/mmHg) using EndoFLIP

    Measured: During index procedure, after fundoplication

  10. Distensibility index on EndoFLIP, on follow-up

    Distensibility index (mm2/mmHg) using EndoFLIP, at follow-up endoscopy

    Measured: 1 year

  11. Maximum diameter on EndoFLIP, premyotomy

    Maximum diameter (mm) on EndoFLIP

    Measured: During index procedure, before myotomy

  12. Maximum diameter on EndoFLIP, post-myotomy

    Maximum diameter (mm) on EndoFLIP

    Measured: During index procedure, after myotomy

  13. Maximum diameter on EndoFLIP, post-fundoplication

    Maximum diameter (mm) on EndoFLIP

    Measured: During index procedure, after fundoplication

  14. Maximum diameter on EndoFLIP, on follow-up

    Maximum diameter (mm) on EndoFLIP, at follow-up endoscopy

    Measured: 1 year

  15. GERD-HRQL score

    Symptom and quality of life score relating to GERD The score ranged from 0-50 with higher score signifying more severe GERD symptom / worse quality of life

    Measured: 1 month, 3 month, 6 month and 1 year

  16. GERD-RSI score

    Symptom and quality of life score relating to GERD The score ranged from 0-45 with higher score signifying more severe GERD symptom

    Measured: 1 month, 3 month, 6 month and 1 year

  17. GERD-Q score

    Symptom and quality of life score relating to GERD The score is ranged from 0-18 with the higher score signifying more symptom of GERD

    Measured: 1 month, 3 month, 6 month and 1 year

  18. Use of proton pump inhibitor post-procedure

    Number of participants who are on regular / as required / not on PPI

    Measured: 1 month, 3 month, 6 month, and 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Sep 2023
  2. Study start1 Dec 2023
  3. Primary completion31 Oct 2025 (estimated)
  4. Study completion31 Oct 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Randomised controlled trial
Masking
None (open label)
Enrolment
81 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06042127
Sponsor's protocol ID
2023 145-T
Status last verified
Nov 2024
First submitted
6 Sep 2023
Last updated
3 Dec 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing POEM-F and Conventional POEM in people with Achalasia, run by Chinese University of Hong Kong at 7 sites in 4 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 3 Dec 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 7 sites in India, United States, China, Hong Kong. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Hon Chi Yip, FRCSEd (35052627, hcyip@surgery.cuhk.edu.hk), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Post-procedure rate of gastroesophageal reflux (time frame: 1 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Dec 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in